Sandwiched between the election and Thanksgiving, the US IPO market had another slow week for new offerings. Meanwhile, recent news and a string of initial filings signals that companies are preparing for IPOs in December and early 2017. Those plans...read more
Motif Bio, a late-stage biotech developing antibiotics for multi-drug resistant bacteria, raised $17 million by offering 2.4 million ADSs at $6.98, or $25 million including a European placement. Motif, which is listed on London's AIM market (MTFB),...read more
Motif Bio, a late-stage biotech developing antibiotics for multi-drug resistant bacteria, lowered the proposed deal size for its upcoming IPO on Monday. The New York, NY-based company now plans to raise $24 million by offering 2.9 million shares at a price...read more
US IPO Weekly Recap: 6 IPO filings signal a more active December
Sandwiched between the election and Thanksgiving, the US IPO market had another slow week for new offerings. Meanwhile, recent news and a string of initial filings signals that companies are preparing for IPOs in December and early 2017. Those plans...read more
Antibiotic biotech Motif Bio prices initial US offering below original proposal at $6.98
Motif Bio, a late-stage biotech developing antibiotics for multi-drug resistant bacteria, raised $17 million by offering 2.4 million ADSs at $6.98, or $25 million including a European placement. Motif, which is listed on London's AIM market (MTFB),...read more
Antibiotics biotech Motif Bio decreases proposed IPO deal size
Motif Bio, a late-stage biotech developing antibiotics for multi-drug resistant bacteria, lowered the proposed deal size for its upcoming IPO on Monday. The New York, NY-based company now plans to raise $24 million by offering 2.9 million shares at a price...read more
US IPO Week Ahead: 4 micro-cap companies make second attempts at IPOs
Apart from the three companies that were on the IPO calendar last week, the only new addition is micro-cap biotech Accelerated Pharma. ...read more